Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Michael J. Detke net worth and biography

Michael Detke Biography and Net Worth

Insider of Cortexyme

Michael Detke, M.D., Ph.D., has served as our Chief Medical Officer since 2018. Dr. Detke has over 25 years of research experience, primarily in clinical drug development. Prior to joining Cortexyme, he served as the Chief Medical Officer at Embera NeuroTherapeutics, CoMentis Pharmaceuticals, and MedAvante, Inc. Dr. Detke started his pharma/biotech industry career Eli Lilly, Inc. where he served as head of early phase development of CNS products, with responsibilities for one of the industry’s largest CNS pipelines. Prior to that, he served as Senior Medical Director overseeing Phase 3 development for Cymbalta and Phase 4 for Prozac. Dr. Detke is also an Adjunct Clinical Professor of Psychiatry at Indiana University School of Medicine. He attended Yale University undergraduate, the University of Pennsylvania for his M.D. and Ph.D., and Harvard for psychiatry residency. He’s published >70 manuscripts in peer-reviewed journals and is an active member of several scientific societies.

What is Michael J. Detke's net worth?: The estimated net worth of Michael J. Detke is at least $17,800.00 as of August 10th, 2021. Dr. Detke owns 10,000 shares of Cortexyme stock worth more than $17,800 as of December 22nd. This net worth approximation does not reflect any other assets that Dr. Detke may own. Learn More about Michael J. Detke's net worth.
How do I contact Michael J. Detke?: The corporate mailing address for Dr. Detke and other Cortexyme executives is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. Cortexyme can also be reached via phone at (650) 910-5717 and via email at [email protected]. Learn More on Michael J. Detke's contact information.
Has Michael J. Detke been buying or selling shares of Cortexyme?: Michael J. Detke has not been actively trading shares of Cortexyme over the course of the past ninety days. Most recently, Michael J. Detke sold 10,000 shares of the business's stock in a transaction on Tuesday, August 10th. The shares were sold at an average price of $100.00, for a transaction totalling $1,000,000.00. Following the completion of the sale, the insider now directly owns 10,000 shares of the company's stock, valued at $1,000,000. Learn More on Michael J. Detke's trading history.
Who are Cortexyme's active insiders?: Cortexyme's insider roster includes Michael Detke (Insider), Stephen Dominy (Insider), David Lamond (Director), Christopher Lowe (CFO), Casey Lynch (CEO), and Margaret Mcloughlin (Director). Learn More on Cortexyme's active insiders.

Michael J. Detke Insider Trading History at Cortexyme

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/10/2021	Sell	10,000	$100.00	$1,000,000.00	10,000
7/6/2021	Sell	40,861	$53.54	$2,187,697.94

Michael J. Detke Buying and Selling Activity at Cortexyme

Cortexyme Company Overview

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Today's Range

Now: $1.78

$1.74

$1.85

50 Day Range

MA: $1.61

$0.69

$2.16

2 Week Range

Now: $1.78

$1.78

$40.66

Volume

106,261 shs

Average Volume

620,672 shs

Market Capitalization

$53.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4

First JFK… next Elon?

From Porter & Company | Ad